RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MESSA E
Collezione AOU San Luigi di Orbassano

Items : 10

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. in HemaSphere / Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. eCollection 2020 Oct.

2020
ASL Torino 5
ASL Biella
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
ASL Città di Torino
ASL Torino 4
AOU Alessandria
AOU Novara

Santini V; Tafuri A; Selleri C; Rivellini F; Secchi R; Sciumé M; Sarlo C; Riva M; Poloni A; Pilo F; Pelizzari A; Palumbo GA; Musto P; Oliva E; Messa E; Niscola P; Molteni A; Mancini S; Frattini F; Gaidano V; Guaragna G; Latagliata R; Gumenyuk S; Finelli C; Giai V; Fianchi L; Filì C; Ferrara IL; Fava C; et alii...

Emerging drugs for chronic myeloid leukemia. in Expert opinion on emerging drugs / Expert Opin Emerg Drugs. 2010 Jun;15(2):175-84. doi: 10.1517/14728211003621220.

2010
AOU San Luigi di Orbassano

Cilloni D; Messa E; Rotolo A; Saglio G;

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. in Haematologica / Haematologica. 2010 Aug;95(8):1308-16. doi: 10.3324/haematol.2009.016824. Epub 2010 Jun 9.

2010
AOU San Luigi di Orbassano

Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D;

The long-term durability of molecular responses in patients with FIP1L1-PDGFRA chronic heosinophilic leukemia treated with imatinib: The italian hes0203 experience after a 4-year follow-up in Haematologica

2009
AOU San Luigi di Orbassano

Rondoni M; Cilloni D; Paolini S; Ottaviani E; Messa F; Piccaluga PP; Merante S; Buccisano F; Titibelli M; Vigna E; Spadea A; Messa E; Pane F; Saglio G; Lauria F; Baccarani M; Martinelli G;

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. in Haematologica / Haematologica. 2008 Jun;93(6):921-4. doi: 10.3324/haematol.12165. Epub 2008 Apr 28.

2008
AOU San Luigi di Orbassano

Cilloni D; Messa F; Arruga F; Defilippi I; Gottardi E; Fava M; Carturan S; Catalano R; Bracco E; Messa E; Nicoli P; Diverio D; Sanz MA; Martinelli G; Lo-Coco F; Saglio G;

A young man with persistent eosinophilia. in Internal and emergency medicine / Intern Emerg Med. 2007 Jun;2(2):107-12. doi: 10.1007/s11739-007-0030-1.

2007
AOU San Luigi di Orbassano

Messa E; Cilloni D; Saglio G;

Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. in Annals of the New York Academy of Sciences / Ann N Y Acad Sci. 2006 Nov;1089:411-23. doi: 10.1196/annals.1386.030.

2006
AOU San Luigi di Orbassano

Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G;

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid in Cancer

2005
AOU San Luigi di Orbassano

Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A;

Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia. in Annals of the New York Academy of Sciences / Ann N Y Acad Sci. 2004 Dec;1028:423-31. doi: 10.1196/annals.1322.050.

2004
AOU San Luigi di Orbassano

Saglio G; Morotti A; Mattioli G; Messa E; Giugliano E; Volpe G; Rege-Cambrin G; Cilloni D;

Myelodysplastic syndromes. in Annals of the New York Academy of Sciences / Ann N Y Acad Sci. 2004 Dec;1028:400-8. doi: 10.1196/annals.1322.048.

2004
AOU San Luigi di Orbassano

Cilloni D; Messa F; Carturan S; Arruga F; Defilippi I; Messa E; Gottardi E; Saglio G;